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Key Clinical Message
We report the first case of pregnancy in a pediatric patient with catecholiminer-
gic polymorphic ventricular tachycardia (CPVT). Pregnant adolescents with
CPVT are at high risk for NSVT and malignant VT during pregnancy, despite
antiarrhythmic medication. They may receive multiple implantable cardioverter
defibrillator (ICD) therapies. Such patients require close monitoring with
special care during the first trimester.
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Introduction
There is a paucity of information regarding pregnant
women with an implantable cardioverter defibrillator
(ICD) who have received documented discharges during
pregnancy. Catecholiminergic polymorphic ventricular
tachycardia (CPVT) is a calcium channelopathy that
causes malignant polymorphic ventricular tachycardia
(PVT) with adrenergic stimulation, and can be triggered
by emotional or physical stress such as may be experi-
enced in pregnancy [1, 2]. We report a case of a pregnant
teenager with CPVT who received documented ICD dis-
charges during her pregnancy.
Case Report
In early 2004 a 12-year-old female with a history of syn-
cope during exercise was evaluated. Physical examination
was normal. Her resting 12-lead electrocardiogram and
echocardiogram were within normal limits. Her cardiac
MRI demonstrated normal findings without evidence of
arrythmogenic right ventricular dysplasia (ARVD). Her
pattern of highly malignant PVT triggered by adrenergic
stimulation in the absence of structural heart disease or
ECG abnormalities in a patient less than 40 years of age
was thought consistent with CPVT [3].
She underwent an electrophysiologic (EP) study, which
demonstrated inducible and reproducible non-sustained
polymorphic ventricular tachycardia. An ICD (Medtronic
Marquis defibrillator model # 7230CX, Medtronic plc,
Dublin, Ireland) was placed in the left infraclavicular area
and a ventricular lead (model 6947) was implanted in the
right ventricle via the left subclavian vein. Successful con-
version of tachycardia with a 10 J shock was recorded.
The patient was placed on daily atenolol.
Since implantation, the patient has had multiple epi-
sodes of appropriate device therapy for PVT, all of which
were preceded by a provoking event. This was frequently
followed by a subsequent shock because of catecholamine
release from the first shock.
In early 2009 the patient conceived her first child at
the age of 17 years. She was seen in the pacemaker clinic
at 10 weeks gestation by last menstrual period (LMP). At
that time she was on atenolol, 50 mg twice a day. Her
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device settings that day were pacing mode VVI with a
lower rate of 45 bpm, amplitude of 2.5 V, pulse width of
0.6 msec, and a sensitivity of 0.3 mV. Therapy parameters
were VT zone 162–207 bpm and VF zone >207 bpm.
Pacing history revealed that she was ventricularly sensed
97.5% of the time and ventricularly paced 2.5% of the
time since her last visit.
Interrogation revealed three events of sustained PVT
requiring device therapy. The events occurred at approxi-
mately 2 weeks gestation, 4 weeks gestation and 9 weeks
gestation. Each event was reversed with a single 20 J
shock. All events occurred while walking and during the
day time. The patient said that she forgot to take atenolol
on the day of the third event. For each event, the patient
stated that she felt very dizzy, and then the defibrillator
went off. She continued to remain dizzy with poor exer-
cise tolerance for approximately 30–60 sec following the
discharge. Evaluation of her electrocardiograms revealed
that she continued to have erratic rhythm with short
bursts of ventricular tachycardia during that period before
reverting to normal sinus rhythm (Fig. 1).
She additionally had thirty events of non-sustained
ventricular tachycardia (NSVT), and two which the device
determined to be supraventricular tachycardia (SVT).
Eighteen of these events occurred during the third month
of pregnancy. At this visit she was switched to metoprolol
50 mg twice a day because of a better safety profile in
pregnancy.
She called 4 days later saying metoprolol was making
her feel dizzy, and she could feel her pacemaker “pacing
her a lot more.” Metoprolol was decreased to 50 mg once
daily. She called again a week later, saying she was still
feeling unwell and her pacemaker “was pacing all the
time.” Both times, she denied any defibrillator therapies.
After consultation with the high-risk obstetric staff, she
was resumed on her original dose of atenolol, 50 mg
twice daily.
Her 23-week ultrasound showed a fetal heart rate of
140 bpm and a PR interval of 100 msec. A biophysical
profile at 34 weeks gestation revealed a 2416 g fetus
which was approximately at the 35th percentile for
weight. The amniotic fluid index was estimated to be ade-
quate at 9.5–13 cm. Expected date of delivery by LMP
and ultrasound differed by 4 days.
She was seen in the pacemaker clinic a week prior to
her planned cesarean section, which was approximately
6 months from her previous visit. Device settings were
unchanged. Pacing history revealed that she was ventricu-
larly sensed 99.2% of the time and ventricularly paced
0.8% of the time. She had only three events of NSVT
without symptoms, no ventricular fibrillation event and
no ICD therapies. She was on atenolol 25 mg in the
morning and 50 mg in the evening at this visit.
She underwent planned cesarean section under spinal
anesthesia with 20 lg of Fentanyl delivered spinally at
38 weeks gestation. Bupivicaine 1% was used for local
anesthesia at site of needle injection. 2 mg of Midazolam
and 0.15 mg of Morphine were used preoperatively for
mild sedation and pain control. Intravenous bicitra and
phenergan were used intraoperatively to relieve patient
nausea. The patient delivered a healthy male newborn
with a birth weight of 3075 g. Apgar scores were 8 and 9
at 1 and 5 min, respectively. There were no complications
during or after delivery, and mother and baby were dis-
charged uneventfully. A 3-month follow up in the gyne-
cology and cardiac clinics of mother and baby revealed
no adverse outcome except a new diagnosis of maternal
post-partum depression.
Discussion
The use of the ICD has allowed an increased number of
young women with life-threatening cardiac arrhythmias
to reach their reproductive years. Few studies have exam-
ined pregnancy in women with ICD’s [4–7]. All have
small samples, adult populations and a narrow variety of
cardiac disorders. Adolescent pregnancies have a higher
propensity for adverse outcome, even in otherwise-healthy
teenagers [8]. Such pregnancies may require even closer
monitoring in the context of known cardiovascular
disease.
Only one other case of pregnancy in a woman with
CPVT and an ICD was found in the literature as part of
a recent review of 12 adult patients [4]. This patient did
not receive any ICD discharges, and did not experience
any episodes of ventricular arrhythmias or ventricular
pacing during her pregnancy (Boule et al., personal com-
munication). Other reports on arrythmogenic conditions
during pregnancy such as long-QT syndrome and ARVD
have suggested ventricular events requiring ICD therapy
in the second trimester, approximately around 20 weeks
[9, 10]. In contrast, our patient experienced three appro-
priate therapies and several events of antitachycardia pac-
ing during the first trimester. Hormonal, cardiovascular
and autonomic changes might play a role in exacerbation
of arrhythmias during pregnancy [10, 11]. In particular,
circulating estrogen has been proposed to increase
myocardial sensitivity to catecholamines [12]. This may
make patients with CPVT more sensitive to ventricular
electrical events than other arrhythmogenic conditions,
including other primary electrical diseases. However, the
current scarcity of literature precludes any evidence-based
presumptions regarding the pattern of arrhythmias during
pregnancy in CPVT on the basis of other arrhythmogenic
conditions [9, 13]. Important differences in physiology
and endocrinology in adolescent pregnancy from adults
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are well-documented [8, 14]. These may all be factors in
the poor control of ventricular arrhythmias in our
patient. We additionally propose that the development of
tolerance to the rapid cardiovascular, hormonal or auto-
nomic changes induced by pregnancy may be different in
adolescents compared to adults. Adolescent physiology
may, in fact, be slower to adapt to these multiple changes
thereby increasing their risk of electrical events early on.
This premise is supported by our observation that the
arrhythmias decreased as the pregnancy progressed
despite no significant changes in medical management,
possibly due to a better cardiovascular tolerance. A better
and quicker adaptation may also be the reason for Boule
et al.’s adult patient having a significantly different course
of pregnancy.
Our case indicates that the highest risk for ventricular
events may be during the first trimester. Also, teenage
pregnancies may behave completely differently from
adults, as is suggested by the key differences between our
patient and the one reported by Boule et al. Based on
these observations, we recommend closer monitoring of
non-adult patients with CPVT early in pregnancy. As
such, any “high-risk pregnancy” team for such patients
should include a cardiologist on all first trimester visits.
These patients may be appropriate candidates for aggres-
sive remote monitoring, suggested by recent reports to
offer opportunity for faster action in case of adverse
events, and also prevent inappropriate therapies [15].
Our experience suggests metoprolol may not be as
effective as atenolol during pregnancy in CPVT, by caus-
ing more side effects and patient discomfort. Boule
et al.’s patient was maintained successfully on high dose
nadolol (personal communication). Our use of atenolol
did not result in adverse fetal outcome, suggesting it
may be a safe alternative. However, dose optimization of
beta blockers during pregnancy may be required to
Figure 1. ECG lead showing a ventricular fibrillation event. Failure of antitachycardia pacing was followed by degeneration into ventricular
fibrillation and ICD therapy (red arrow). Erratic rhythm with bursts of ventricular tachycardia continued after the ICD therapy before
spontaneously reverting to normal sinus rhythm. TS, ventricular sensing of VT zone; FD, ventricular fibrillation detection; FS, ventricular sensing of
FVT zone; TF, ventricular sensing of VF zone; TD, ventricular tachycardia detection; Rx, therapy (Defibrillation 20.2J 9 1); VF, ventricular
fibrillation; VT, ventricular tachycardia; VS, normal R-wave sensing.
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achieve better antiarrhythmic control, and prevent
unnecessary ICD therapies. Neither our patient nor that
of Boule et al. required antibradycardia pacing, despite
close to maximal doses of beta blockers. The importance
of adhering to medication should be emphasized at every
cardiology and obstetric visit. In our case, missing a sin-
gle dose may have resulted in symptomatic malignant
VT requiring ICD therapy within a few hours. Sustained
VT requiring device intervention within a short time-
frame of discontinuing beta blockers has also been
reported elsewhere [16, 17]. Furthermore, it would also
be reasonable to assume that nadolol may have been an
important factor in preventing malignant VT in Boule
et al.’s patient.
Pacemaker and ICD parameters should be individual-
ized for pregnant patients based on the characteristics of
their prior events. However, where such information may
not be available, our settings may be effective to maintain
a patient with CPVT during pregnancy. Boule et al. main-
tained their patient at somewhat comparable settings of
VVI 40 bpm, VT zone 200–250 bpm and VF zone
>250 bpm. However, their higher VF and VT thresholds
are untested for appropriate response to malignant VT in
such a clinical situation.
ICD therapies and frequent ventricular pacing did not
result in adverse fetal outcome in our patient. This may
be a combined effect of the low amount of current deliv-
ered by ICD’s and a high fetal fibrillatory threshold [18].
Conclusions
Our case report is the first report of pregnancy in a pedi-
atric patient with CPVT. It is also the first identifiable
report of ICD therapies during pregnancy in a CPVT
patient of any age. This case report provides information
which may be critical in managing such patients. We
conclude that adolescents with CPVT are at high risk for
both NSVT and malignant VT during pregnancy, despite
antiarrhythmic medication. We recommend close moni-
toring of such patients throughout pregnancy with special
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